Today: 20 May 2026
Browse Category

NASDAQ:JAZZ 25 August 2025 - 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks reported its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combinations outperformed trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The triple-combination arm also improved overall survival. Jazz Pharmaceuticals plans to file for FDA approval in the first half of 2026. ZYME shares jumped 30–50% pre-market on the news.
17 November 2025
····
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes will acquire Avadel for $18.50 per share in cash, plus a $1.50 contingent payout, valuing the deal at about $2.1 billion. Avadel’s LUMRYZ sales are projected at $265–$275 million in 2025, with 3,100 patients on therapy. AVDL shares surged to near a 52-week high after the Jazz settlement and Alkermes news. Halper Sadeh LLC is investigating whether the offer undervalues Avadel.
22 October 2025
·····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Go toTop